
About this episode
When Vanderbilt University Medical Center began to consider how big data and precision medicine were going to impact both research and development and clinical care, it struck on the idea of building a large-scale biobank and tying it to its store of millions of electronic health records. That ultimately led to the founding of Nashville Bioscience, a for-profit subsidiary of the medical center. We spoke to Leeland Ekstrom, co-founder and CEO of NashBio, about the company’s data collection methods, the significance of the alliance it's developed with leading biopharmaceutical companies, and how it's enabling a transformation of drug development with data.
Get every episode summarized
Each time The Bio Report publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from The Bio Report

Resetting Severe Allergies at Their Cellular Source
The Bio Report

Innovating ADCs with Dual Targeting and Smarter Delivery
The Bio Report

Targeting the Brain’s Immune System in Alzheimer’s Disease
The Bio Report

How Gilead Is Building Durable Oncology and Immunology Franchises
The Bio Report